HIV gp120 Neutralizing Antibodies Targeting Alpha5-Helix Epitope
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine development faces challenges such as reversion of attenuated virus vaccines, partial immune response, lack of cellular immunity, and the variability and mutability of HIV, which have hindered the creation of effective therapeutic and prophylactic treatments.
Innovation Solution
Development of neutralizing antibodies directed to epitopes on the HIV gp120 envelope protein, specifically those binding to the gp120core region, which are derived from non-progressor and slow-progressor patients, to elicit a protective immune response against HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If attenuated virus vaccines are used, then immune response is elicited, but reversion occurs and protection is incomplete
Solution Approach 1:
The patent extracts the protective immunogenic components (gp120 envelope protein epitopes) from the complete HIV virus structure. By using only the purified envelope glycoprotein gp120 as vaccine antigen, the harmful viral replication and reversion risks are eliminated while maintaining the ability to elicit protective neutralizing antibodies against the virus.
Solution Approach 2:
The patent uses recombinant gp120 protein as an intermediary substance that mediates the immune response without requiring live virus replication. This recombinant protein serves as a safe surrogate that can be produced in controlled systems (e.g., yeast or bacterial expression systems) and administered to elicit protective immunity without the risks of attenuated virus vaccines.
2Productivity
If conventional monoclonal antibody techniques are used, then antibodies are produced, but broad neutralizing activity is limited
Solution Approach 1:
The patent employs preliminary immunization of animals with specific HIV gp120 envelope proteins to generate immune responses before isolating and characterizing the neutralizing monoclonal antibodies. This preliminary immune activation ensures that the resulting antibodies have broad neutralizing activity against multiple HIV strains, overcoming the limitations of direct hybridoma techniques without preliminary immunization.
3Measurement precision
If vaccines target single epitopes, then specific immune response is generated, but variability and mutability of HIV reduce effectiveness
Solution Approach 1:
The patent identifies and utilizes multiple conserved epitopes on the HIV gp120 envelope protein that are universally recognized across different HIV strains. The vaccine composition includes immunogens targeting these conserved regions (such as the CD4 binding site and other conserved determinants), enabling the vaccine to elicit broadly neutralizing antibodies that are effective against diverse HIV variants despite the virus's mutability.
Data Source
AI summary
Broad neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV, especially the preparation and use of highly neutralizing antibodies directed to HIV gp120 envelope protein, in the vaccination and treatment of HIV-infected patients.